Sun Pharma stock faces an INR 150.0 billion debt decision

Published on 10/08/2026 at 09:18 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Sun Pharma stock faces an INR 150.0 billion funding decision on October 12, 2026. Q1 FY27 revenue rose 10.5 percent to INR 153.0 billion.

Sun Pharma, INE044A01036, Illustration mit AI erstellt.

Sun Pharma (ISIN INE044A01036) was trading at INR 1,758.30 on NSE on October 8, 2026, at 12:47 p.m. IST, down 1.27 percent from the previous close. The immediate catalyst is a proposed INR 150.0 billion non-convertible debenture issue that the board will consider on October 12, 2026.

Board weighs INR 150.0 billion issue

Reuters reported on October 7, 2026, that Sun Pharmaceutical Industries would consider raising up to INR 150.0 billion through non-convertible debentures at the October 12 board meeting. The proposal is equivalent to INR 15,000 crore, converted into billions, and adds a financing decision to the company's acquisition and specialty-drug agenda.

The proposed securities would be listed, rated, unsecured and redeemable. The board meeting date is also listed as an upcoming corporate event in the company's market disclosures, giving investors a concrete checkpoint for the size, structure and use of the planned funding.

Q1 growth remains the counterweight

DSIJ reported that Q1 FY27 revenue from operations reached INR 153.0 billion, converted from INR 15,300 crore, up 10.5 percent year over year. Reported profit after tax reached INR 29.11 billion, converted from INR 2,911 crore, up 26.4 percent over the same period.

The same report put Q1 FY27 EBITDA at INR 42.96 billion and the EBITDA margin at 28.1 percent, down 130 basis points year over year. That combination matters for the funding decision because revenue and profit growth provide operating support, while the lower margin keeps execution and financing discipline central to the next update.

Stock remains below yearly high

Sun Pharma's current market capitalization is INR 4.2 trillion as of October 8, 2026. The stock's 52-week range is INR 1,583.70 to INR 2,046.90, leaving the latest price INR 288.60 below the yearly high and INR 174.60 above the yearly low.

NSE identifies Sun Pharmaceutical Industries Limited under ISIN INE044A01036, with SUNPHARMA as its equity symbol and pharmaceuticals as its basic industry.